drugset / Trial / NCT05158335
Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of MBX 2109 in Healthy Adult Subjects
RandomizedSequentialDouble-blindBasic science
Summary
The purpose of this trial is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple doses of MBX 2109 in healthy volunteers. This study includes 2 parts. Part A involves a single dose of MBX 2109 taken as a subcutaneous (SC) injection just under the skin. Part B involves repeat doses of MBX 2109 taken as a SC injection just under the skin. Each participant will enroll in only one part.
Timeline
- Start
- 2021-11-10
- Primary completion
- 2023-06-20
- Completion
- 2023-06-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Canvuparatide | Protein / enzyme biologic | 50 ug | Subcutaneous |
| Subject | Canvuparatide | Protein / enzyme biologic | 150 ug | Subcutaneous |
| Subject | Canvuparatide | Protein / enzyme biologic | 200 ug | Subcutaneous |
| Subject | Canvuparatide | Protein / enzyme biologic | 300 ug | Subcutaneous |
| Subject | Canvuparatide | Protein / enzyme biologic | 460 ug | Subcutaneous |
| Subject | Canvuparatide | Protein / enzyme biologic | 600 ug | Subcutaneous |
| Subject | Canvuparatide | Protein / enzyme biologic | 900 ug | Subcutaneous |
Indications
No indication recorded.